Category

Investing

Category

DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high…